Appendix 4D & Half-Year Financial Statements
Filed with ASX · · 21 pages · English
There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the consolidated entity after providing for income tax amounted to $4,811,335 (31 December 2024: $1,533,422). 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declare
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Response to ASX Query Letter
- $9m placement to advance US biodefence opportunity
- FDA confirms Galidesivir approval pathway
- Quarterly Appendix 4C and Activities Report
- US Patent Granted for Galidesivir in filoviridae viruses
Later from Island Pharmaceuticals
- Trading Halt
- US Government collaboration for Galidesivir development
- Antiviral pipeline expansion through strategic collaboration
- Island Bolsters US Biodefence Readiness Ahead of Trials
- Island Adds Biodefence Leader as Filovirus Risks Escalate
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals